CRISPR Pioneer, Home Secretary of the U.S. National Academy of Sciences, IEEE Medal of Honor Recipient and other experts joins Cardea Bio‘s Innovation Council.
With the vision of linking computers up to the LIVE signals of Biology, Cardea now adds an advisory team of Key Opinion Leaders covering all the cross disciplinary efforts being done.
10.06.2020 San Diego, CA: Cardea Bio Inc., who is using graphene-based Biology-gated Transistors (Cardean Transistors™) to directly link the live signals that run biology up to electronics and computers, today announced the Cardea Innovation Council. The Council will serve as an advisory body to guide and help the Cardea team of talents to continue the breakthroughs being made via Cardea’s core technology, Cardean Transistors. The council members will also participate in the Company’s Innovation Partnership Program on relevant projects. The Council consists of a body of Key Opinion Leaders and experts from diverse science and technical fields and will bring a depth of knowledge to aid Cardea in building the most complete Tech+Bio Communication Chipsets and Infrastructure available for current and future generations.
Professor Susan Wessler
Distinguished Professor of Genetics and the Neil and Rochelle Campbell Chair for Innovation in Science Education at the University of California Riverside. In 2011 she was elected Home Secretary of the U.S. National Academy of Sciences (NAS), the first woman to hold this position in its 150-year history. She is a plant molecular geneticist known for her contributions to the field of transposon biology and plant genome evolution.
Among the very first to discover and characterize the CRISPR-Cas9 complex and recognize its editing potential for “DNA surgery” in many life science applications. His pioneer work was recognized with several international awards including the Kavli Prize. Since CRISPR-Chip is an important chipset type for Cardea, his expertise regarding CRISPR is important in improving fast and precise (amplification-free) DNA and RNA detection.
Dr. Kurt Petersen
Founder and CTO of numerous MEMS (Micro-ElectroMechanical System) companies, including NovaSensor, Verreon and molecular testing company Cepheid. Kurt was recently awarded the IEEE Medal of Honor for his contribution to the field of MEMS. Cardean Transistors are very similar to MEMS in many regards and Kurt’s experience with MEMS as it applies to biotechnology will elevate Cardea’s chip designs, scalability and capabilities.
Dr. Phil Cotter
Fellow of the American College of Medical Genetics and Genomics as well as founder and Principal of ResearchDx. Dr. Cotter has been a leader in developing sequencing as a clinical diagnostics tool as the Director of Illumina Clinical Services Laboratory, and through ResearchDx, a leader in development of companion diagnostics based on DNA, RNA and protein biomarkers.
Dr. Lauge Farnaes
As Head of Medical Affairs at IDbyDNA, and Medical Doctor & Researcher formally at Rady Children’s Genomic Institute with expertise in genetic disorders, infectious disease detection, and nucleic acid-based diagnostics, Dr. Farnaes has among other things helped pioneer the use of Rapid Whole Genome Sequencing to diagnose rare genetic disorders in children.
Dr. Elia Stupka
A visionary Key Opinion Leader in bringing the most advanced forms of big data and analytics to healthcare. Dr. Stupka’s work has contributed to the understanding of the human genome, transcriptome, and the development of gene-therapeutics. His understanding of data and its role in enhancing the value of new technology will help steer Cardea’s data management capabilities and add value to every Innovation Partner application.
Dr. Paul Grint
Chairman of the Innovation Council and Chairman of the Board of Directors of Cardea. Dr. Grint has served on the Boards of Illumina, AmpliPhi Biosciences, and as the CEO of several companies. Dr. Grint’s ability to see the early potential in technology served Illumina well when Next Generation Sequencing was in its infancy as it will Cardea with its Biology-gated Transistors.
“Cardea’s core technology is really the convergence of many highly complex technical fields such as life science, data analytics, and semiconductor technology.” says Dr. Grint. “In order for Cardea to be successful in its mission to elevate the world’s ability to gain new insight into biology, we need the best from every field. The Innovation Council will elevate Cardea’s capabilities across all of these fields.”
The news of Cardea’s Innovation Council comes only weeks after the company announced the first close of their A2 round and first commercial “Powered by Cardea” product launch. This is a major move for Cardea on its mission to continue developing even more products together with their Innovation Partners. To learn more about the Council, visit Cardea’s website.
About Cardea Bio
Cardea is linking biology directly up to computers for the very first time by building a Tech+Bio Infrastructure and offering chipsets based on proprietary Biology-gated Transistors, or Cardean Transistors™. These transistors leverage graphene, a nanomaterial that in contrast to the common semiconductor material silicon, is biocompatible and a near perfect conductor due to only being one atom thick. It that way replaces optical static observations with interactive live-streams of multi-omics signal analysis, representing a new life science observation paradigm where multi-omics data-streams will be the new norm instead of most of the current standard technologies that are single-omics frozen-in-time datasets. Together with their Innovation Partners, Cardea can link biology directly to compute power and convert real-time biological signals to digital information, allowing for immediate biological insight and a new generation of applications Linking up to Life.